US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kailera Therapeutics

11.61

+1.6116.10%

Post-market: 11.54-0.0700-0.60%19:49 EDT

Volume:2.18M

Turnover:24.60M

Market Cap:1.50B

PE:-5.15

High:11.81

Open:10.13

Low:9.98

Close:10.00

52wk High:28.23

52wk Low:9.76

Shares:129.54M

Float Shares:44.92M

Volume Ratio:1.52

T/O Rate:4.86%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2543

EPS(LYR):-7,819.9811

ROE:-36.90%

ROA:-22.73%

PB:1.34

PE(LYR):0.00

Loading ...

Overview Company News Filings

Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)

TD Cowen Reaffirms Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)

Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M

Benzinga Earnings

Kailera Q1 FY26 net loss more than quadruples to $78.87 million

Kailera Therapeutics Inc - Q1 Net Loss $78.9 Mln

THOMSON REUTERS

Kailera Therapeutics Inc - Reports Positive Topline Data From Phase 3 Hrs-7535 and Phase 1 Hrs-4729 Trials

THOMSON REUTERS

Kailera Therapeutics Inc - Cash on Hand Expected to Fund Operations Into Mid-2028

THOMSON REUTERS

Press Release: Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates

Kailera Therapeutics, Inc. (KLRA) Receives a Buy from TD Cowen

Analysts Offer Insights on NA Companies: Arxis, Inc. Class A (ARXS) and Kailera Therapeutics, Inc. (KLRA)

ADVISORY-Research alert on Kailera Therapeutics withdrawn

Kailera Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating; Price Target $57

THOMSON REUTERS

This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst

Kailera presents Phase 1 ribupatide injection data supporting global Phase 3 KaiNETIC program at ADA

Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions

Kailera Therapeutics initiated with an Outperform at Evercore ISI

Kailera Therapeutics Initiated at Outperform by Evercore ISI Group

Kailera Therapeutics Initiated at Overweight by JP Morgan

JPMorgan Initiates Kailera Therapeutics at Overweight With $30 Price Target

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/KLRA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KLRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics","latestPrice":11.61,"timestamp":1791576000000,"preClose":10,"halted":0,"volume":2182259,"hourTrading":{"tag":"盘后","latestPrice":11.54,"preClose":11.61,"latestTime":"19:49 EDT","volume":40356,"amount":468730.5049,"timestamp":1791589772631,"change":-0.07,"changeRate":-0.006029,"amplitude":0.022394},"delay":0,"changeRate":0.16099999999999995,"floatShares":44921899,"shares":129537300,"eps":-2.254252,"marketStatus":"Market Closed","change":1.61,"latestTime":"10-09 16:00:00 EDT","open":10.13,"high":11.81,"low":9.98,"amount":24599826.640537,"amplitude":0.183,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.254252,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":10,"preHourTrading":{"tag":"盘前","latestPrice":10,"preClose":10,"latestTime":"05:33 EDT","volume":102,"amount":1020,"timestamp":1791538395851,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":11.54,"preClose":11.61,"latestTime":"19:49 EDT","volume":40356,"amount":468730.5049,"timestamp":1791589772631,"change":-0.07,"changeRate":-0.006029,"amplitude":0.022394},"volumeRatio":1.5214762252735545,"impliedVol":0.7988,"impliedVolPercentile":0.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","floatShares":44921899,"roa":"-22.73%","roe":"-36.90%","lyrEps":-7819.9811,"volumeRatio":1.5214762252735545,"shares":129537300,"dividePrice":0,"high":11.81,"amplitude":0.183,"preClose":10,"low":9.98,"week52Low":9.76,"pbRate":"1.34","week52High":28.2271,"institutionHeld":0,"latestPrice":11.61,"eps":-2.254252,"divideRate":0,"volume":2182259,"delay":0,"ttmEps":-2.254252,"open":10.13,"prevYearClose":16,"prevWeekClose":10.39,"prevMonthClose":11.42,"prevQuarterClose":11.42,"fiveDayClose":10.39,"twentyDayClose":13.94,"sixtyDayClose":18.32,"earningDate":1793721600000,"earningTime":"盘后"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRA\",params:#limit:5,,,undefined,":[{"date":"2026-11-04","symbol":"KLRA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1793826000000,"name":null,"time":"Post-Mkt","dateTimestamp":1793768400000,"actualEps":null},{"market":"US","date":"2026-08-12","symbol":"KLRA","fiscalQuarterEnding":"2026/06","expectedEps":-0.74,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-1.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1783483200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRA","date":"2026-10-09","current":-5.150267,"percent":1,"low":-21.871461,"twenty":-18.692055,"median":-11.897285,"eighty":-7.064366,"high":-4.436859,"avg":-12.839091,"sd":5.511911,"marketCap":1296436760},"quantilePoints":[{"date":"2026-04-17","current":-12.669466,"twenty":-12.511098,"median":-12.273546,"eighty":-12.035993,"marketCap":1887180368},{"date":"2026-04-24","current":-20.824025,"twenty":-20.917019,"median":-20.433783,"eighty":-14.17085,"marketCap":3101842710},{"date":"2026-05-01","current":-21.741015,"twenty":-21.413894,"median":-20.305085,"eighty":-18.829635,"marketCap":3238432850},{"date":"2026-05-08","current":-19.540824,"twenty":-21.576784,"median":-20.824025,"eighty":-19.524523,"marketCap":2910703445},{"date":"2026-05-15","current":-18.697273,"twenty":-21.521865,"median":-20.058623,"eighty":-18.676401,"marketCap":2785052251},{"date":"2026-05-22","current":-18.332024,"twenty":-21.403595,"median":-19.540824,"eighty":-18.304195,"marketCap":2730646579},{"date":"2026-05-29","current":-19.949555,"twenty":-21.097481,"median":-19.520448,"eighty":-18.332024,"marketCap":2971585983},{"date":"2026-06-05","current":-18.253756,"twenty":-20.940268,"median":-19.530636,"eighty":-18.332024,"marketCap":2718988220},{"date":"2026-06-12","current":-16.992777,"twenty":-20.824025,"median":-19.392985,"eighty":-17.13192,"marketCap":2531159115},{"date":"2026-06-18","current":-16.636224,"twenty":-20.511831,"median":-18.758148,"eighty":-17.050173,"marketCap":2478048816},{"date":"2026-06-26","current":-12.75669,"twenty":-20.227867,"median":-18.684228,"eighty":-17.050173,"marketCap":2676825461},{"date":"2026-07-02","current":-12.855483,"twenty":-20.165517,"median":-18.622605,"eighty":-16.764931,"marketCap":2697555958},{"date":"2026-07-10","current":-12.9728,"twenty":-20.033041,"median":-18.410291,"eighty":-15.433812,"marketCap":2722173424},{"date":"2026-07-17","current":-11.311837,"twenty":-19.949555,"median":-18.314631,"eighty":-13.521103,"marketCap":2373641938},{"date":"2026-07-24","current":-10.743775,"twenty":-19.944337,"median":-17.453687,"eighty":-12.859187,"marketCap":2254441579},{"date":"2026-07-31","current":-10.527665,"twenty":-19.923466,"median":-17.13192,"eighty":-12.704356,"marketCap":2209093616},{"date":"2026-08-07","current":-11.651439,"twenty":-19.849563,"median":-17.071044,"eighty":-11.79378,"marketCap":2444903022},{"date":"2026-08-14","current":-7.973035,"twenty":-19.724778,"median":-16.992777,"eighty":-11.573639,"marketCap":2329696857},{"date":"2026-08-21","current":-7.746755,"twenty":-19.603438,"median":-16.640572,"eighty":-11.334065,"marketCap":2263578582},{"date":"2026-08-28","current":-8.221499,"twenty":-19.532674,"median":-16.131833,"eighty":-11.014222,"marketCap":2402297316},{"date":"2026-09-04","current":-6.983615,"twenty":-19.497291,"median":-13.667441,"eighty":-10.594351,"marketCap":2040591460},{"date":"2026-09-11","current":-6.615356,"twenty":-19.448642,"median":-13.506901,"eighty":-10.353542,"marketCap":1932987209},{"date":"2026-09-18","current":-5.732421,"twenty":-19.325153,"median":-12.9728,"eighty":-8.138973,"marketCap":1674996293},{"date":"2026-09-25","current":-5.315357,"twenty":-18.99469,"median":-12.812261,"eighty":-7.882523,"marketCap":1553131238},{"date":"2026-10-02","current":-4.893855,"twenty":-18.745973,"median":-12.669466,"eighty":-7.29952,"marketCap":1429969746},{"date":"2026-10-09","current":-4.436859,"twenty":-18.692055,"median":-11.897285,"eighty":-7.064366,"marketCap":1296436760}],"updateTime":1791636076056},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2639168796","title":"Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2639168796","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639168796?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:05","pubTimestamp":1779998700,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., May  28, 2026  (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3303260/0/en/Kailera-Therapeutics-to-Present-at-the-2026-Jefferies-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029874061.USD","BK4137","LABU","BK4585","XLV","KLRA","BK4139","LU0128526141.USD","BK4581","HCSG","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639697868","title":"Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2639697868","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639697868?lang=en_us&edition=fundamental","pubTime":"2026-05-28 23:55","pubTimestamp":1779983733,"startTime":"0","endTime":"0","summary":"Jefferies analyst Roger Song maintained a Buy rating on Kailera Therapeutics, Inc. today and set a price target of $48.00. Song covers the Healthca...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-their-buy-rating-for-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-their-buy-rating-for-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638673576","title":"TD Cowen Reaffirms Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638673576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638673576?lang=en_us&edition=fundamental","pubTime":"2026-05-27 13:15","pubTimestamp":1779858913,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Yaron Werber maintained a Buy rating on Kailera Therapeutics, Inc. yesterday. The company’s shares closed yesterday at USD21.57. W...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-reaffirms-their-buy-rating-on-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-reaffirms-their-buy-rating-on-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","TD","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638052823","title":"Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M","url":"https://stock-news.laohu8.com/highlight/detail?id=2638052823","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638052823?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:50","pubTimestamp":1779828607,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(3.65) per share which missed the analyst consensus estimate of $(0.68) by 444.78 percent as R&amp;D spend Jumps to $70.9M.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52795466/kailera-therapeutics-q1-eps-3-65-misses-0-68-estimate-as-r-d-spend-jumps-to-70-9m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638540348","title":"Kailera Q1 FY26 net loss more than quadruples to $78.87 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2638540348","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638540348?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:02","pubTimestamp":1779825771,"startTime":"0","endTime":"0","summary":"Kailera posted a net loss of $78.87 million in Q1 2026, widening from a $17.98 million loss a year earlier.Research and development expenses more than doubled to $70.87 million, while general and administrative costs rose 33.88% to $13.79 million.Cash, cash equivalents and marketable securities totaled $581.9 million as of March 31, with IPO proceeds expected to fund operations into mid-2028.Advanced obesity pipeline with five late-stage global trials initiated, including the KaiNETIC Phase 3 program for once-weekly ribupatide injection.Reported new partner-led topline data in China for oral GLP-1 agonist KAI-7535 in type 2 diabetes and first-in-human Phase 1 results for injectable tri-agonist KAI-4729.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDLpWX5D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00016","IE00BN0W2W23.USD","BK4112","IE00B1G9TL16.USD","LU0229494975.USD","IE00BKPKM429.USD","SG9999002463.SGD","BK1559","LU0224508324.USD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","IE00BSPPW651.USD","IE00B1G9TM23.USD","80016","BK4585","LU2210150020.SGD","SG9999010052.SGD","KLRA","LU1539696804.USD","LU2226123490.SGD","IE00BN0W2T93.GBP","LU2088748376.SGD","LU1163227579.USD","LU2095319765.USD","LU2088747725.USD","BK1521","SG9999014013.SGD","BK1601","BK1216","LU1163227496.USD","LU2088747998.USD","SG9999014005.SGD","SG9999009997.SGD","LU0886674414.USD","IE00B64PRP62.GBP","SG9999010078.USD","LU0315179316.USD","03145","LU0096374516.USD","BK4588","LU2088748020.USD","SG9999014039.USD","IE00BN0W2V16.EUR","LU2088748293.HKD","BK4139","LU2226123227.USD","LU1560770973.SGD","SUHJY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638540558","title":"Kailera Therapeutics Inc - Q1 Net Loss $78.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2638540558","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638540558?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:02","pubTimestamp":1779825720,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA8JWMQX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638540510","title":"Kailera Therapeutics Inc - Reports Positive Topline Data From Phase 3 Hrs-7535 and Phase 1 Hrs-4729 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2638540510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638540510?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:02","pubTimestamp":1779825720,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA8JWMQX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638154062","title":"Kailera Therapeutics Inc - Cash on Hand Expected to Fund Operations Into Mid-2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2638154062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638154062?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:02","pubTimestamp":1779825720,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA8JWMQX:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638540384","title":"Press Release: Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2638540384","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638540384?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:02","pubTimestamp":1779825720,"startTime":"0","endTime":"0","summary":"-- Important progress across four clinical-stage programs demonstrating. -- Initiated five late-stage global clinical trials in obesity, including. -- Reported positive topline clinical data from three trials conducted by. our partner Hengrui in China, including new topline data from Phase 3. trial of oral small molecule GLP-1 receptor agonist HRS-7535 . in type 2 diabetes, and first-in-human topline data from Phase 1 trial. -- Cash on hand, including IPO proceeds, is expected to fund operations into. Renaud, continued, \"These achievements, combined with our successful IPO, have positioned us with the capital and operational strength to continue advancing multiple programs in parallel. We are focused on maintaining this momentum and executing across our clinical programs as we work to deliver differentiated therapies for the treatment of obesity.\". living with obesity or overweight. Data is anticipated in 2028.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMI","BK4139","BK4157","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637353143","title":"Kailera Therapeutics, Inc. (KLRA) Receives a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2637353143","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637353143?lang=en_us&edition=fundamental","pubTime":"2026-05-22 00:55","pubTimestamp":1779382537,"startTime":"0","endTime":"0","summary":"In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Kailera Therapeutics, Inc., with a price target of $57.00. Werber...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/kailera-therapeutics-inc-klra-receives-a-buy-from-td-cowen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/kailera-therapeutics-inc-klra-receives-a-buy-from-td-cowen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","BK4139","TD","COWN","BK4585","KLRA","BK4207","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636418018","title":"Analysts Offer Insights on NA Companies: Arxis, Inc. Class A (ARXS) and Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636418018","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636418018?lang=en_us&edition=fundamental","pubTime":"2026-05-18 00:41","pubTimestamp":1779036113,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Arxis, Inc. Class A (ARXS) and Kailera Therapeutics, Inc. (K...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-arxis-inc-class-a-arxs-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-arxis-inc-class-a-arxs-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA","BK4187","BK4139","BK4141","NA","ARXS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635762235","title":"ADVISORY-Research alert on Kailera Therapeutics withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2635762235","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635762235?lang=en_us&edition=fundamental","pubTime":"2026-05-14 13:25","pubTimestamp":1778736345,"startTime":"0","endTime":"0","summary":"ADVISORY-Research alert on Kailera Therapeutics withdrawnMay 14 (Reuters) - An alert on TD Cowen starting coverage on Kailera Therapeutics Inc KLRA.O is dated and has been withdrawn. There will be no ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nFWN41R08Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635625727","title":"Kailera Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating; Price Target $57","url":"https://stock-news.laohu8.com/highlight/detail?id=2635625727","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635625727?lang=en_us&edition=fundamental","pubTime":"2026-05-14 13:08","pubTimestamp":1778735305,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nFWN41R08Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635751444","title":"This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2635751444","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635751444?lang=en_us&edition=fundamental","pubTime":"2026-05-14 02:43","pubTimestamp":1778697780,"startTime":"0","endTime":"0","summary":"William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/05/13/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/05/13/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/05/52539772/this-weight-loss-drug-challenger-could-follow-eli-lillys-playbook-analyst","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/05/52539772/this-weight-loss-drug-challenger-could-follow-eli-lillys-playbook-analyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["IE0009355771.USD","IE00B2B36J28.USD","LU0823434583.USD","LU0316494557.USD","LU0256863902.USD","LU0109394709.USD","IE00BFSS8Q28.SGD","IE00BN29S564.USD","LU0225283273.USD","LU2089283258.USD","LU2211815571.USD","LU0640476718.USD","LU1814569148.SGD","LU2168563687.JPY","LU2271345857.HKD","LU0109391861.USD","LU2023251221.USD","SG9999014898.SGD","LU2471134952.CNY","LU2750360641.GBP","LU0353189680.USD","LU0823434740.USD","LU0122379950.USD","ELIS","LU0820561818.USD","SG9999018865.SGD","LU0094547139.USD","SG9999013999.USD","LU2168564495.EUR","IE00B775H168.HKD","IE00BFSS7M15.SGD","LU0079474960.USD","LU2746668461.USD","LU2756315318.SGD","LU1868836591.USD","LU2087625088.SGD","LU2168564065.EUR","BK4585","LU0006306889.USD","LU0353189763.USD","LU0354030511.USD","LU2462157665.USD","LU1917777945.USD","LU1035775433.USD","LU2063271972.USD","IE00BJT1NW94.SGD","LU1366192091.USD","IE00B4R5TH58.HKD","LU0256863811.USD","BK4581","SG9999018857.SGD","SGXZ31699556.SGD","LLYX","LU1548497426.USD","LU2552382132.HKD","LU1323610961.USD","LU2896262040.SGD","LU1145028129.USD","LU0203202063.USD","IE00BJLML261.HKD","LU0097036916.USD","SG9999001176.USD","LU0471298777.SGD","LU1720051017.SGD","LU2602419157.SGD","LU2552382058.USD","IE00BKDWB100.SGD","LU1974910355.USD","LU1291159041.SGD","LU2023250330.USD","LU0266013472.USD","LU2023250504.SGD","LLII","LU2111349929.HKD","LU2746668974.SGD","LU0823416689.USD","LU0889565916.HKD","LU0964807845.USD","LU0417517546.SGD","IE00B4JS1V06.HKD","LU0203201768.USD","LLYZ","LU0689472784.USD","LU2456880835.USD","LU2491050154.USD","LU1868837136.USD","LU1983299246.USD","LU1093756325.SGD","BK4533","LU1551013342.USD","LU0289739699.SGD","LU0787776722.HKD","IE00BKPKM429.USD","IE0004445239.USD","LU1064131342.USD","IE00BJJMRY28.SGD","LU0106261372.USD","LU0323591593.USD","LU1232071149.USD","LU2237443978.SGD","LU0320765992.SGD","IE00BK4W5L77.USD","LU2756315664.SGD","SG9999001176.SGD","LU2028103732.USD","LU1061106388.HKD","LU1551013425.SGD","ELIL","IE00BFTCPJ56.SGD","LU1069344957.HKD","LU0943347566.SGD","LU1868836914.USD","IE00BK4W5M84.HKD","LU1804176565.USD","LU2264538146.SGD","LU2361044865.SGD","LU0456855351.SGD","LU0471298694.HKD","LU2361045086.USD","LU0096364046.USD","LU1720051108.HKD","LU0385154629.USD","LU0882574139.USD","IE0005OL40V9.USD","LU2361044949.HKD","LU2237438978.USD","SG9999014906.USD","SGXZ99366536.SGD","BK4599","LU2461242641.AUD","BK4534","LU2324357040.USD","LU2112291526.USD","BK4588","BK4007","LU2750360997.AUD","LU1127390331.HKD","LU2106854487.HKD","LU2236285917.USD","IE00BJJMRX11.SGD","LU0320765059.SGD","IE0004445015.USD","LU1629891620.HKD","LU0158827948.USD","LU0238689110.USD","LU1868836757.USD","SGXZ81514606.USD","LU2468319806.SGD","IE00B7KXQ091.USD","LU0672654240.SGD","BK4516","LU0882574055.USD","LU0466842654.USD","LU0786609619.USD","IE00B1BXHZ80.USD","LU1280957306.USD","LU2089984988.USD","LU2237443622.USD","LU0820562030.AUD","LU1712237335.SGD","LU1093756168.USD","LU0114720955.EUR","LU0058720904.USD","LU2213496289.HKD","LU1988902786.USD","LU2491049909.HKD","SG9999015986.USD","LU2168564222.USD","SGXZ51526630.SGD","LU0158827781.USD","LU0234572021.USD","LU0061475181.USD","LU0354030438.USD","LU2237443465.HKD","LU1057294990.SGD","LU2237443549.SGD","SG9999015978.USD","LU1989771016.USD","LU2471134523.USD","LU0820561909.HKD","LU1267930730.SGD","LU0133085943.USD","SG9999014880.SGD","IE0002141913.USD","LU2108987350.USD","IE00BJJMRZ35.SGD","LU2168564149.EUR","LU2417539215.USD","LU0198837287.USD","LU2471134796.USD","SG9999015945.SGD","LU0210536198.USD","LU2491050071.SGD","IE00B1XK9C88.USD","LU2237443382.USD","LLY","IE00BWXC8680.SGD","SGXZ57979304.SGD","LU2089284900.SGD","LU2360106947.USD","SG9999014914.USD","GB00BDT5M118.USD","LU2237443895.HKD","LU2357305700.SGD","LU2471134879.HKD","SG9999017495.SGD","LU2265009873.SGD","LU0683600562.USD","LU0708995401.HKD","LU0432979614.USD","LU1623119135.USD","SG9999015952.SGD","LU1868837300.USD","KLRA","LU1023059063.AUD","LU2552382215.SGD","IE0001KFT4U8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635789072","title":"Kailera presents Phase 1 ribupatide injection data supporting global Phase 3 KaiNETIC program at ADA","url":"https://stock-news.laohu8.com/highlight/detail?id=2635789072","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635789072?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:31","pubTimestamp":1778671895,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics announced 2 clinical data poster presentations on ribupatide, its dual GLP-1/GIP agonist program for obesity and overweight, scheduled for June 5-8, 2026 at American Diabetes Association 86th Scientific Sessions in New Orleans.Results have not yet been presented; Kailera plans to show Phase 1 bridging study data for injectable ribupatide on June 8.Study readout supported initiation of Kailera ongoing global Phase 3 KaiNETIC clinical program, positioning injectable ribupatide as lead near-term value driver in its obesity pipeline.Partner Hengrui Pharma will also present Phase 2 results for oral ribupatide on June 7, expanding optionality across oral and injectable formats without disclosing outcomes in this announcement.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL3vdWDt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014013.SGD","BK4585","BK4588","IE00BN0W2T93.GBP","NDAQ","BK4139","LU2210149790.SGD","IE00BGHQF748.EUR","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","SG9999014039.USD","KLRA","IE00BKPKM429.USD","SG9999014005.SGD","LU2095319765.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","SG9999014021.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635878901","title":"Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=2635878901","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635878901?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:30","pubTimestamp":1778671800,"startTime":"0","endTime":"0","summary":"Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and ove","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293890/0/en/Hengrui-Pharma-and-Kailera-Therapeutics-Announce-Clinical-Data-Presentations-at-the-American-Diabetes-Association-86th-Scientific-Sessions.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","BK4117","KLRA","BK4139","AFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635724525","title":"Kailera Therapeutics initiated with an Outperform at Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2635724525","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635724525?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:50","pubTimestamp":1778601012,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Umer Raffat initiated coverage of Kailera Therapeutics (KLRA) with an Outperform rating and no price target Kailera is “making...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-initiated-with-an-outperform-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-initiated-with-an-outperform-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634245888","title":"Kailera Therapeutics Initiated at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2634245888","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634245888?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:36","pubTimestamp":1778600160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KLRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 11:36 ET (15:36 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634248399","title":"Kailera Therapeutics Initiated at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2634248399","media":"Dow Jones","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634248399?lang=en_us&edition=fundamental","pubTime":"2026-05-12 22:39","pubTimestamp":1778596740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KLRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 10:39 ET (14:39 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634213491","title":"JPMorgan Initiates Kailera Therapeutics at Overweight With $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2634213491","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634213491?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:16","pubTimestamp":1778584605,"startTime":"0","endTime":"0","summary":"JPMorgan Initiates Kailera Therapeutics at Overweight With $30 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JPM","PGF","KLRA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":90,"code":"91000000","status":"200"}]}}